(Q43622754)

English

Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

25 November 2017

Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial (English)

1 reference

Europe PubMed Central

25 November 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

J A Liu Yin

1

1 reference

Europe PubMed Central

25 November 2017

K Wheatley

2

1 reference

Europe PubMed Central

25 November 2017

J K Rees

3

1 reference

Europe PubMed Central

25 November 2017

A K Burnett

4

1 reference

Europe PubMed Central

25 November 2017

UK MRC Adult Leukemia Working Party

5

1 reference

Europe PubMed Central

25 November 2017

language of work or name

0 references

publication date

1 June 2001

1 reference

Europe PubMed Central

25 November 2017

British Journal of Haematology

1 reference

Europe PubMed Central

25 November 2017

113

1 reference

Europe PubMed Central

25 November 2017

713-726

1 reference

Europe PubMed Central

25 November 2017

3

1 reference

Europe PubMed Central

25 November 2017

Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02785.X

21 January 2018

Expression of mdr1 and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02785.X

21 January 2018

Treatment strategies in acute myeloid leukemia (AML). B. Second line treatment

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02785.X

21 January 2018

Expression of the multidrug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotype

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02785.X

21 January 2018

Treatment of the elderly patient with acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02785.X

21 January 2018

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02785.X

21 January 2018

Overexpression of the mdr1 gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporin-A.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02785.X

21 January 2018

MDR1 gene expression and treatment outcome in acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02785.X

21 January 2018

Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02785.X

21 January 2018

MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02785.X

21 January 2018

Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02785.X

21 January 2018

Reversal of drug-resistance by cyclosporin-A in a patient with acute myelocytic leukaemia.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02785.X

21 January 2018

Outcome for children with relapsed acute myeloid leukaemia following initial therapy in the Medical Research Council (MRC) AML 10 trial. MRC Childhood Leukaemia Working Party

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02785.X

21 January 2018

A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02785.X

21 January 2018

Identifiers

10.1046/J.1365-2141.2001.02785.X

1 reference

Europe PubMed Central

25 November 2017

1 reference

Europe PubMed Central

25 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43622754&oldid=2101945772"